Matches in Nanopublications for { ?s ?p "[ These data strongly suggest that UGT1A7 and/or UGT1A9 genotypes may be predictors of response and toxicity in CRC patients treated with capecitabine plus irinotecan. Specifically, patients with genotypes conferring low UGT1A7 activity and/or the UGT1A9 (]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP80589.RAY-J3VqIlqi3Tr3GWCPJxv31Hqnptc-0Y2r9kwLvfX_8130_assertion description "[ These data strongly suggest that UGT1A7 and/or UGT1A9 genotypes may be predictors of response and toxicity in CRC patients treated with capecitabine plus irinotecan. Specifically, patients with genotypes conferring low UGT1A7 activity and/or the UGT1A9 (]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP80589.RAY-J3VqIlqi3Tr3GWCPJxv31Hqnptc-0Y2r9kwLvfX_8130_provenance.
- NP90621.RAemf_8JvM_HGCQbA2MZP55yIg5ZjqGjulbRBTW1jSB2Y130_assertion description "[ These data strongly suggest that UGT1A7 and/or UGT1A9 genotypes may be predictors of response and toxicity in CRC patients treated with capecitabine plus irinotecan. Specifically, patients with genotypes conferring low UGT1A7 activity and/or the UGT1A9 (]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP90621.RAemf_8JvM_HGCQbA2MZP55yIg5ZjqGjulbRBTW1jSB2Y130_provenance.
- NP80558.RAhektjU5wL7nrdQg_KErf1KHbxCx3Pzy1lbcRetIZaqY130_assertion description "[ These data strongly suggest that UGT1A7 and/or UGT1A9 genotypes may be predictors of response and toxicity in CRC patients treated with capecitabine plus irinotecan. Specifically, patients with genotypes conferring low UGT1A7 activity and/or the UGT1A9 (]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP80558.RAhektjU5wL7nrdQg_KErf1KHbxCx3Pzy1lbcRetIZaqY130_provenance.
- NP90623.RAttx_M2XYYHobl9tqj1O6O_VO8zk5UonQIil8s35DpAI130_assertion description "[ These data strongly suggest that UGT1A7 and/or UGT1A9 genotypes may be predictors of response and toxicity in CRC patients treated with capecitabine plus irinotecan. Specifically, patients with genotypes conferring low UGT1A7 activity and/or the UGT1A9 (]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP90623.RAttx_M2XYYHobl9tqj1O6O_VO8zk5UonQIil8s35DpAI130_provenance.